Subsequent events	9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]
Subsequent events	13. Subsequent events 2024 ATM Program In August 2024, the Company entered into a sales agreement with TD Securities (USA) LLC (f/k/a Cowen and Company LLC) (TD Cowen), to sell shares of our common stock, from time to time, through an at-the-market equity offering program (the 2024 ATM). In October 2025, the Company sold an aggregate of 3,521,018 shares of common stock under the 2024 ATM resulting in gross proceeds of $185.7 million. After deducting commissions and expenses of $2.8 million, net proceeds to the Company were $182.9 million.

Subsequent events

9 Months Ended

Sep. 30, 2025

13.

Subsequent events

2024 ATM Program

In August 2024, the Company entered into a sales agreement with TD Securities (USA) LLC (f/k/a Cowen and Company LLC) (TD Cowen), to sell shares of our common stock, from time to time, through an at-the-market equity offering program (the 2024 ATM). In October 2025, the Company sold an aggregate of 3,521,018 shares of common stock under the 2024 ATM resulting in gross proceeds of $185.7 million. After deducting commissions and expenses of $2.8 million, net proceeds to the Company were $182.9 million.

Revolution Medicines, Inc. 10-Q